Edition:
United States

KaloBios Pharmaceuticals Inc (KBIO.OQ)

KBIO.OQ on NASDAQ Stock Exchange Global Market

--USD
--
Change (% chg)

-- (--)
Prev Close
--
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
--
52-wk Low
--

Summary

Name Age Since Current Position

Cameron Durrant

55 2016 Chairman of the Board, Chief Executive Officer

David Tousley

61 2016 Interim Chief Financial Officer

Geoffrey Yarranton

63 2016 Executive Vice President - Research and Development

Morgan Lam

51 2016 Chief Scientific Officer

Patrick Crutcher

2015 Head - Business Development

Donald Joseph

61 2013 Chief Legal Officer

Edward Painter

2015 Head - Communications and Investor Relations

Ronald Barliant

2016 Independent Director

Biographies

Name Description

Cameron Durrant

Dr. Cameron Durrant M.D., is Chairman of the Board, Chief Executive Officer of the Company. Dr. Durrant has been a director and Chairman of the Board of the Company since January 7, 2016. He also serves as the lead independent director of Immune Pharmaceuticals Inc., and as a board member of Bexion Pharmaceuticals, Alcyone Life Sciences and ReliefBand Technologies. He has previously served as CEO of ECR Pharmaceuticals, Founder, Chairman and CEO of PediatRx, CEO of PediaMed Pharmaceuticals and is the Founder of Taran Pharma Limited. He has been a senior executive at Johnson and Johnson, Pharmacia Corporation, GSK and Merck. Dr. Durrant earned his medical degree from the Welsh National School of Medicine, Cardiff, UK, his DRCOG from the Royal College of Obstetricians and Gynecologists, London, UK, his MRCGP from the Royal College of General Practitioners, London, UK, his DipCH from the Melbourne Academy, Australia and his MBA from Henley Management College, Oxford, UK.

David Tousley

Mr. David L. Tousley serves as Interim Chief Financial Officer of the Company. Mr. Tousley has served as an independent consultant to the Company since May 2016. Prior to his work with the Company, Mr. Tousley served as acting Chief Financial Officer and then Executive Vice President and Chief Financial Officer of oncology-focused pharmaceutical company DARA Biosciences, Inc. (“DARA”) from March 2012 through DARA’s acquisition by Midatech Pharma PLC in December 2015, and as Executive Vice President and Chief Financial Officer of DARA’s successor Midatech Pharma US Inc. from December 2015 through March 2016. Mr. Tousley also served as Secretary, Treasurer and Chief Financial Officer of PediatRx, Inc. from July 2010 until October 2012 and as Principal of Stratium Consulting Services, where he specialized in strategic and financial planning and management, corporate governance and business development, from 2007 through March 2013. Previously, Mr. Tousley served as Executive Vice President and Chief Financial Officer of airPharma, LLC and held senior management positions at PediaMed Pharmaceuticals, Inc., AVAX Technologies, Inc. and Pasteur Meriux Connaught (now Sanofi Pasteur). Mr. Tousley received an MBA from Rutgers Graduate School of Management and received his undergraduate degree from Rutgers College. Mr. Tousley is a certified public accountant in the state of New Jersey.

Geoffrey Yarranton

Dr. Geoffrey T. Yarranton, Ph.D., is Executive Vice President - Research and Development of KaloBios Pharmaceuticals Inc. He was Chief Scientific Officer of the Company. Prior to this, he co-founded Celscia Therapeutics in 2003 and served as Chief Executive Officer before merging Celscia with KaloBios in 2004. Following the merger, Dr. Yarranton served as the Chief Executive Officer of KaloBios from 2004 to 2006 and as a member of our Board from 2004 to 2009. Dr. Yarranton has over 30 years of experience in the biotechnology industry working both in Europe and the United States. Prior to co-founding Celscia, Dr. Yarranton served as Senior Vice President of Research and Development at Coulter Pharmaceutical. Following the acquisition of Coulter Pharmaceutical by Corixa Corporation, Dr. Yarranton became Senior Vice President of Research and Development and Site Director of the South San Francisco site. Dr. Yarranton spent 16 years at Celltech Therapeutics in the United Kingdom, where he led their research activities as the Director of Research. Dr. Yarranton holds a Bachelor of Science degree in biology from the University of Leicester in the United Kingdom and a Ph.D. in the enzymology of DNA replication, from the National Institute for Medical Research, United Kingdom.

Morgan Lam

Mr. Morgan Lam serves as Chief Scientific Officer of the Company. He was Chief Operating Officer of KaloBios Pharmaceuticals, Inc. Mr. Lam joined the Company in 2015 as Head of Clinical Operations and Interim Development Leader. In such positions, he has supervised the Company’s clinical programs and applied his extensive experience in clinical research in the pharmaceutical industry to the Company’s product development. Prior to his employment with the Company, Mr. Lam served as Executive Director, Medical Affairs of Geron Corporation, a biopharmaceutical company, from May 2010 to May 2015.

Patrick Crutcher

Mr. Patrick Crutcher is Head - Business Development of KaloBios Pharmaceuticals, Inc. Patrick Crutcher is also a Founder and Head of Business Development for Turing Pharmaceuticals and was a key member of the business development team at Retrophin. Additionally, Mr. Crutcher was a healthcare consultant focused on private and publicly traded biotechnology companies.

Donald Joseph

Mr. Donald R. Joseph is Chief Legal Officer of Kalobios Pharmaceuticals, Inc. Mr. Joseph has 20 years of biopharmaceutical industry experience, including major global health non-profit organizations. Prior to KaloBios, he was Chief Executive Officer of BIO Ventures for Global Health (BVGH), a non-profit organization engaging private industry in global health initiatives, from February to November 2012 and Chief Operating Officer from April 2010 to January 2012. He is currently Chairman of the BVGH board of directors. He has also served as Chief Operating Officer at the Institute for OneWorld Health, a non-profit drug development company. In both organizations, he was also responsible for the legal function in addition to his other responsibilities. He previously served as general counsel, corporate secretary, and in other senior management roles at biopharmaceutical companies, including Abgenix, Inc., which was acquired by Amgen Inc., and Renovis Inc., a former subsidiary of Evotec AG. Before entering the life sciences industry, Mr. Joseph practiced business law for a number of years in major firms, including as an international partner at Baker & McKenzie, one of the world's largest law firms. Mr. Joseph received his J.D. degree from the University of Texas School of Law, with honors.

Edward Painter

Mr. Edward Painter is Head - Communications and Investor Relations of the Company. Edward Painter is also Head of Communications and Investor Relations with Turing Pharmaceuticals. His experience includes 25 years of working with biopharma investors at numerous investment banks and managing his own investment firm. His career began with Salomon Brothers and Goldman Sachs and was most recently with UBS.

Ronald Barliant

Mr. Ronald Barliant is Independent Director of the Company. Mr. Barliant, an attorney who is of counsel with the law firm of Goldberg Kohn in Chicago, IL , previously served as a United States bankruptcy judge for the Northern District of Illinois from 1988 to 2002. Mr. Barliant has also served as adjunct faculty at John Marshall Law School and is a frequent lecturer and author on bankruptcy-related matters.